Greenwich LifeSciences Highlights Phase III FLAMINGO-01 Data At AACR 2026

Greenwich LifeSciences presented new open-label data from its pivotal Phase III FLAMINGO-01 trial of GLSI-100 at the AACR Annual Meeting 2026. The update reinforces clinical progress for the breast cancer recurrence-prevention immunotherapy, though the article provides no efficacy or safety numbers. The news is supportive for sentiment but is unlikely to move the broader market materially.

Analysis

Greenwich LifeSciences presented new open-label data from its pivotal Phase III FLAMINGO-01 trial of GLSI-100 at the AACR Annual Meeting 2026. The update reinforces clinical progress for the breast cancer recurrence-prevention immunotherapy, though the article provides no efficacy or safety numbers. The news is supportive for sentiment but is unlikely to move the broader market materially.